Lyka Labs Ltd
Ticker: LYKALABS
Risky
48/100
☆ Add to Watchlist
Investing Reference
Price
94.04
Market Cap
335.63
Debt/Equity
0.3647
ROE %
9.206
PB
3.2068
Promoter %
58.163
Pledge %
0.000
1Y Rev Growth %
24.927
5Y Rev Growth %
16.235
NP Margin %
5.692
NP Margin 5Y Avg %
-0.692
Trading Reference
1M Return %
-2.052
6M Return %
-14.773
1Y Return %
-35.167
% Away 52W High
87.782
% Away 52W Low
2.686
Daily Volume
10201
Investment Verdict
Risky
Score 59/100 · Position size: 6%
Higher volatility/weak areas. Consider only a small allocation if risk appetite is high.
Trading Verdict
Avoid
Score 18/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
Summary
Lyka Labs Ltd shows potential for growth in the pharmaceutical sector but faces challenges in profitability and competition.
✅ Positives
- Strong product pipeline in pharmaceuticals
- Growing demand for healthcare products
- Strategic partnerships enhancing market reach
⚠️ Negatives
- High competition in the industry
- Recent decline in profit margins
- Regulatory challenges affecting operations
Verdict
Cautiously optimistic about future performance.
Recommendation: Consider buying on dips.
Upside Probability: 30% | Downside Probability: 20%
Last generated: 30/10/2025
More Options
N
Nectar Lifesciences Ltd
Nectar Lifesciences Ltd shows potential in a growing sector, but faces challenges in consistency and valuation, warranting cautious observation.
View details
A
Aditya BSL Gold ETF
Aditya BSL Gold ETF presents a decent investment opportunity with stable growth potential, though investors should be cautious of governance and execution risks.
View details
S
Saraswati Saree Depot Ltd
Saraswati Saree Depot Ltd shows potential but faces challenges in growth and market sentiment.
View details
A
Almondz Global Securities Ltd
The stock shows potential but is hindered by inconsistent growth and profitability metrics. Caution is advised for new investments.
View details
J
Jainam Ferro Alloys (I) Ltd
Jainam Ferro Alloys (I) Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
M
Menon Pistons Ltd
Menon Pistons Ltd shows potential but faces challenges in growth consistency and valuation. Caution is advised.
View details
E
E Factor Experiences Ltd
E Factor Experiences Ltd presents several risks with inconsistent growth and weak profitability metrics, making it a risky investment at this time.
View details
M
Monarch Surveyors & Engineering Consultants Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment.
View details
H
Hitech Corporation Ltd
Hitech Corporation Ltd shows potential but faces significant risks and challenges in growth and market sentiment.
View details
A
Aion-Tech Solutions Ltd
Aion-Tech Solutions Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics. Caution is advised.
View details
E
ELGI Rubber Co Ltd
ELGI Rubber Co Ltd shows potential for growth but faces several challenges that could impact its performance.
View details
D
Diamines and Chemicals Ltd
Diamines and Chemicals Ltd shows potential for growth but faces several risks that could impact its performance.
View details
Q
Quest Capital Markets Ltd
Quest Capital Markets Ltd presents several risks with inconsistent growth and profitability metrics, alongside governance concerns.
View details
P
Prizor Viztech Ltd
Prizor Viztech Ltd shows potential in a future-ready sector but faces significant risks in growth and profitability, making it a risky investment at this time.
View details
A
Alufluoride Ltd
Alufluoride Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics. Caution is advised due to execution risks.
View details
Y
Yash Optics & Lens Ltd
Yash Optics & Lens Ltd shows potential in a growing sector but faces challenges in profitability and valuation. Caution is advised.
View details
Business Overview
Lyka Labs Ltd is a pioneering player in the Indian biotechnology sector, specializing in innovative healthcare solutions. Catering to a diverse audience, including healthcare providers and patients, Lyka Labs focuses on enhancing the quality of life through advanced medical products. The company is committed to research and development, ensuring that it stays at the forefront of biopharmaceutical advancements. With a strong emphasis on quality and efficacy, Lyka Labs plays a crucial role in addressing critical health challenges in India.
- Innovative biotechnology solutions
- Focus on quality healthcare products
- Strong research and development capabilities
- Addresses critical health challenges
- Committed to improving quality of life
Investment Thesis
Lyka Labs Ltd presents a compelling investment opportunity driven by a strong promoter group with a solid reputation, a significant growth runway in digital services, and attractive valuations compared to its peers. This combination positions the company for robust future performance in the evolving healthcare landscape.
- Promoter group has a proven track record and strong credibility in the industry.
- Digital services segment poised for substantial growth, tapping into increasing healthcare digitization.
- Valuation metrics indicate Lyka Labs is attractively priced relative to industry peers.
- Strong fundamentals and growth potential make it a favorable choice for long-term investors.
- Strategic initiatives are likely to enhance market presence and shareholder value.
Opportunity vs Risk
Opportunities
- Growing demand for health supplements
- Expansion into new markets
- Strong online sales growth
- Innovative product launches
Risks ⚠️
- Intense competition in the sector
- Regulatory changes impacting operations
- Supply chain disruptions
- Fluctuating raw material costs
Peer Perspective
Lyka Labs Ltd trades at a 15% discount to peers like Sun Pharma and Cipla, primarily due to margin volatility. A stable margin and consistent growth could trigger a rerating in its valuation.
Future Outlook
Lyka Labs Ltd is well-positioned for growth, driven by innovative product development and expanding market reach. Successful execution of its strategic initiatives and effective cost control will be crucial to maximizing shareholder value.
AI FAQs for Retail Users
- Q: What does Lyka Labs Ltd do?A: Lyka Labs Ltd is involved in the manufacturing and marketing of pharmaceuticals and healthcare products.
- Q: Is Lyka Labs Ltd a good investment?A: Investing in stocks depends on individual financial goals and market conditions. Research is recommended.
- Q: What are the recent developments in Lyka Labs Ltd?A: Recent developments include new product launches and expansion in distribution channels.
- Q: How can I buy shares of Lyka Labs Ltd?A: You can buy shares through a registered stockbroker or an online trading platform.
- Q: What are the risks of investing in Lyka Labs Ltd?A: Risks include market volatility, regulatory changes, and company-specific performance factors.
📊 Stock Investment Checklist (100 Points)
Lyka Labs Ltd • Updated: 2025-09-17 03:24:44
-
8BusinessHighPharmaceutical sector shows potential but faces regulatory challenges.
-
10GrowthHighInconsistent revenue growth with recent fluctuations.
-
10ProfitabilityHighModerate ROE and ROCE, but cash flow is inconsistent.
-
9ValuationHighP/E ratio is higher than industry average, indicating overvaluation.
-
7BalanceHighDebt levels are manageable, but liquidity is a concern.
-
6GovernanceGoodPromoter holding is decent, but some pledging exists.
-
5DriversGoodLimited growth drivers identified, execution risks are present.
-
1TechnicalsLowWeak market sentiment and low liquidity.
Final Score & Verdict
Score 48 / 100
• Risky
Lyka Labs Ltd presents several risks with inconsistent financial performance and valuation concerns, making it a risky investment at this time.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 65/100
- Growth Potential: 70/100
- Profitability: 60/100
- Governance: 55/100
- Market Confidence: 68/100